| 货号 | 规格 | 价格 | 上海 | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|
| S89238-5mg | 98% | ￥1088.00 | 6 | - | - | - |
|
| S89238-10mg | 98% | ￥1904.00 | 7 | - | - | - |
|
| S89238-25mg | 98% | ￥3808.00 | 4 | - | - | - |
|
| S89238-100mg | 98% | ￥8200.00 | 货期：2-3天 | - | - | - |
|
Topovale is a potent inhibitor of topoisomerase I. Topovale inhibits hypoxia-mediated accumulation of hypoxia-inducible factor-1alpha. Topovale exhibited low nM cytotoxicity against a panel of cancer cells. Topovale cytotoxicity as well as Topovale-induced apoptosis was reduced > 100-fold in CPT-resistant topoisomerase I (TOP1)-deficient P388/CPT45 cells as compared with P388 cells.
| 产品描述： | Topovale is a potent inhibitor of topoisomerase I. Topovale inhibits hypoxia-mediated accumulation of hypoxia-inducible factor-1alpha. Topovale exhibited low nM cytotoxicity against a panel of cancer cells. Topovale cytotoxicity as well as Topovale-induced apoptosis was reduced > 100-fold in CPT-resistant topoisomerase I (TOP1)-deficient P388/CPT45 cells as compared with P388 cells. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Topoisomerase | ||||||||||||||||||||
| 参考文献： | 1. Feng W, Satyanarayana M, Tsai YC, Liu AA, Liu LF, LaVoie EJ. Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c ,h][1,6]naphthyridin-6-one iodide. Eur J Med Chem. 2009 Sep;44(9):3433-8. doi: 10.1016/j.ejmech.2009.02.004. PubMed PMID: 19299037; PubMed Central PMCID: PMC2766012. 2. Kurtzberg LS, Battle T, Rouleau C, Bagley RG, Agata N, Yao M, Schmid S, Roth S, Crawford J, Krumbholz R, Ewesuedo R, Yu XJ, Wang F, Lavoie EJ, Teicher BA. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors. Mol Cancer Ther. 2008 Oct;7(10):3212-22. doi: 10.1158/1535-7163.MCT-08-0568. PubMed PMID: 18852125. 3. Li TK, Houghton PJ, Desai SD, Daroui P, Liu AA, Hars ES, Ruchelman AL, LaVoie EJ, Liu LF. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res. 2003 Dec 1;63(23):8400-7. PubMed PMID: 14679002. 4. Zhou W, Dai Z, Chen Y, Wang H, Yuan Z. High-Dimensional descriptor selection and computational QSAR modeling for antitumor activity of ARC-111 analogues Based on Support Vector Regression (SVR). Int J Mol Sci. 2012;13(1):1161-72. doi: 10.3390/ijms13011161. PubMed PMID: 22312310; PubMed Central PMCID: PMC3269744. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京